Kothandaraman Narasimhan

Kothandaraman Narasimhan

Auto-generated profile, based on publicly available information

Kothandaraman Narasimhan

Highthroughput Genomics and Proteomics, Centre for Excellence in Genomic Medicine Research, Saudi Arabia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Neoplasia
Verified
Journal Article
Open access
CZChangqing Zhao
Changqing Zhao
LALoganath Annamalai
Loganath Annamalai
CGChangfa Guo
Changfa Guo
NKNarasimhan Kothandaraman
Narasimhan Kothandaraman
SKStephen Chee Liang Koh
Stephen Chee Liang Koh
MCMahesh Choolani
Mahesh Choolani
This study was conducted to evaluate the prognostic significance of haptoglobin levels in the overall survival of patients presenting with various stages of epithelial ovarian cancer. We employed an in-house sandwich enzyme-linked immunosorbent assay method to determine the concentrations of preoperative haptoglobin and C-reactive protein (CRP) in sera samples obtained from 66 malignant tumors, 60 benign tumors, and 10 normal healthy women. Levels of serum haptoglobin significantly correlated with tumor type (P < .001) and International Federation of Gynecology and Obstetrics stage (P < .05). A significant correlation was observed between clinical stage and patient survival (r = 5.99, P = .026). Our data also indicated that elevated serum haptoglobin levels were associated with poor outcome for overall survival using both univariate and multivariate analyses (P = .048 and P = .036 respectively). Using Pearson's correlation, we have noted that serum CRP concentrations significantly correlated with haptoglobin levels (r(2) = 0.22, P < .001). Immunohistochemical findings and Western blot analyses were compatible with sera levels of haptoglobin in which a higher intensity of staining occurred in late-stage epithelial ovarian cancers. This study provides evidence that preoperative serum levels of haptoglobin could serve as an independent prognostic factor in patients presenting with epithelial ovarian cancer.

1 April 2008 in Journal of Chromatography A
Verified
Journal Article
Closed access
CBChanbasha Basheer
Chanbasha Basheer
KNKothandaraman Narasimhan
Kothandaraman Narasimhan
MYMeihui Yin
Meihui Yin
CZChangqing Zhao
Changqing Zhao
MCMahesh Choolani
Mahesh Choolani
HLHian Kee Lee
Hian Kee Lee

1 February 2011 in Analytica Chimica Acta
Verified
Journal Article
Closed access
SKSivarajan Kanimozhi
Sivarajan Kanimozhi
CBChanbasha Basheer
Chanbasha Basheer
KNKothandaraman Narasimhan
Kothandaraman Narasimhan
LLLin Liu
Lin Liu
SKStephen Koh
Stephen Koh
HLHian Kee Lee
Hian Kee Lee

1 February 2009 in Expert Review of Proteomics
Verified
Journal Article
Closed access
MCMahesh Choolani
Mahesh Choolani
KNKothandaraman Narasimhan
Kothandaraman Narasimhan
VKVaraprasad Kolla
Varaprasad Kolla
SHSinuhe Hahn
Sinuhe Hahn
Proteomics-based identification of biomarkers for fetal abnormalities in maternal plasma, amniotic fluid and reproductive fluids has made significant progress in the past 5 years. This is attributed mainly to advances in various technology platforms associated with mass spectrometry-based techniques. As these techniques are highly sensitive and require only small quantities of body fluids, it is hoped that they will pave the way for the development of effective noninvasive approaches, without subjecting the developing fetus to the same degree of harm as current invasive procedures (e.g., amniocentesis). It is possible that these developments will include same-day analyses, thereby permitting rapid intervention when necessary. To date, a host of body fluids, such as maternal serum and plasma, amniotic fluid, cervical fluid, vaginal fluid, urine, saliva or fetal material, such as placental trophoblast, fetal membranes or cord blood, have been used successfully in the quest to develop markers for a number of pregnancy-related pathologies. In the current review update we focus on the emergence of proteomics as a major platform technology in studying various types of fetal conditions and developing markers for pregnancy-related disorders, such fetal aneuploidy, preterm birth, preeclampsia, intra-amniotic infection and fetal stress. Should the development of these markers be successful, then it is to be envisaged that proteomic approaches will become standard of care for a number of disease conditions associated with feto–maternal health.

1 October 2010 in Pathology
Verified
Journal Article
Closed access
PDF file
KDKakoli Das
Kakoli Das
PLPia Donna Nitullano Lorena
Pia Donna Nitullano Lorena
LNLai Kuan Ng
Lai Kuan Ng
LSLiang Shen
Liang Shen
DLDiana Lim
Diana Lim
MSManuel Salto-Tellez
Manuel Salto-Tellez

19 September 2011 in BMC Systems Biology
Verified
Journal Article
Open access
PDF file
MKMandeep Kaur
Mandeep Kaur
CMCameron Ross MacPherson
Cameron Ross MacPherson
SSSebastian Schmeier
Sebastian Schmeier
KNKothandaraman Narasimhan
Kothandaraman Narasimhan
MCMahesh Choolani
Mahesh Choolani
VBVladimir Bajic
Vladimir Bajic
Background: Our study focuses on identifying potential biomarkers for diagnosis and early detection of ovarian cancer (OC) through the study of transcription regulation of genes affected by estrogen hormone. Results: The results are based on a set of 323 experimentally validated OC-associated genes compiled from several databases, and their subset controlled by estrogen. For these two gene sets we computationally determined transcription factors (TFs) that putatively regulate transcription initiation. We ranked these TFs based on the number of genes they are likely to control. In this way, we selected 17 top-ranked TFs as potential key regulators and thus possible biomarkers for a set of 323 OC-associated genes. For 77 estrogen controlled genes from this set we identified three unique TFs as potential biomarkers. Conclusions: We introduced a new methodology to identify potential diagnostic biomarkers for OC. This report is the first bioinformatics study that explores multiple transcriptional regulators of OC-associated genes as potential diagnostic biomarkers in connection with estrogen responsiveness. We show that 64% of TF biomarkers identified in our study are validated based on real-time data from microarray expression studies. As an illustration, our method could identify CP2 that in combination with CA125 has been reported to be sensitive in diagnosing ovarian tumors.